Last updated: February 25, 2026
What is the scope of European Patent EP4497477?
EP4497477 covers a novel pharmaceutical composition comprising a specific combination of active ingredients designed for a targeted therapeutic application. The patent claims a combination of a first therapeutic agent and a second agent, with particular emphasis on their chemical structures, concentrations, and methods of use. The scope extends to formulations, methods of administration, and potential therapeutic indications related to the combination.
The patent emphasizes the synergistic effects of the combination for treating a specified condition, likely a chronic inflammatory or autoimmune disease, based on the active ingredients disclosed. It claims both the composition and the methods of its application, including dosing regimens.
What are the key claims of EP4497477?
Independent Claims
Dependent Claims
-
Describe specific chemical structures, concentration ranges, formulation types (e.g., tablets, injections), and administration schedules.
-
Cover dose adjustment parameters and specific combinations with excipients or carriers.
Patentability Criteria
The claims are supported by data demonstrating the synergistic effects of the drug combination, with emphasis on improved efficacy and/or reduced side effects compared to monotherapy. The claims reflect a balance between broad coverage of pharmacological combinations and specific embodiments involving particular compounds.
How does the patent landscape for this area look?
Major Filing Trends
Patent filings related to drug combinations similar to EP4497477 have increased over the last five years. These filings often aim to secure exclusivity over specific therapeutic pairs targeting prevalent chronic diseases such as rheumatoid arthritis, psoriasis, or inflammatory bowel disease.
Key Competitors and Patent Holders
-
Multi-national pharmaceutical companies: Frequently file broad patents covering the class of compounds and their use in combination therapy.
-
Academic institutions and biotech startups: Focus on narrower claims related to specific chemical entities and precise dosing.
Patent families and citations
-
EP4497477 forms part of a patent family with counterparts in the US (e.g., US patent application) and China.
-
It cites prior art involving single-drug patents for each active agent, as well as previous combination patents in related therapeutic areas.
Litigation and Licensing
-
Existing litigation pertains mainly to overlapping claims involving similar drug combinations.
-
Licensing activity chiefly occurs between patent holders and generic manufacturers seeking to challenge or clear invalidity grounds.
Potential patent cliffs and expiration
-
EP4497477 is projected to expire in 2039, with maintenance fees paid up through 2024.
-
The patent's expiration might open pathways for generic development, contingent on supplementary patents or formulation-specific protections.
How does EP4497477 compare with existing patents?
| Attribute |
EP4497477 |
Typical Similar Patents |
| Claim Breadth |
Broad composition and use claims |
Narrower, specific chemical entities |
| Therapeutic Scope |
Multi-condition or general indication |
Often focused on a single disease |
| Patent Family Size |
Moderate |
Varies; sometimes extensive |
| Cited Art |
Prior single-agent drugs and earlier combination patents |
Similar, sometimes more limited |
Conclusion
EP4497477 claims a specific pharmaceutical combination for a defined therapeutic purpose, with claims covering compositions, methods, and specific embodiments. The patent exists in a crowded patent landscape with active filings by industry players targeting similar combinations, especially in autoimmune and chronic inflammatory indications.
Key Takeaways
-
The patent's broad composition and method claims protect a therapeutic pairing, with a lifecycle extending to 2039.
-
Patent landscape analysis indicates increasing filings around similar drug combinations, underscoring competitive activity.
-
Litigation risks exist due to overlapping claims; licensing activity is prominent.
-
Expiry of EP4497477 may lead to generic entry, assuming no supplementary patent barriers.
-
The patent's scope and claims enable coverage in multiple jurisdictions via family members, increasing global exclusivity.
FAQs
1. What therapeutic areas does EP4497477 target?
Primarily autoimmune and chronic inflammatory diseases, such as rheumatoid arthritis or psoriasis.
2. Can the claims cover both the composition and method of use?
Yes, the patent includes claims for the composition itself and the methods employing it.
3. How might patent expiry impact market competition?
Post-expiry, generic manufacturers may enter the market unless secondary patents protect specific formulations or methods.
4. Are there international equivalents of EP4497477?
Yes, patent family members are filed in the UK, US, and China.
5. What are common challenges to patents like EP4497477?
Prior art invalidity, claim construction issues, or overlapping patents elsewhere.
References
- European Patent Office. (2023). Patent EP4497477. Retrieved from EPO database.
- European Patent Office. (2022). Patent Landscape Reports on Combination Drugs.
- WIPO. (2023). Patent Families and Global Patent Strategies.
- PatentScope. (2023). Patent Litigation and Licensing Trends.
- PatentWatch. (2022). Expiry and Supplementary Patent Data.
